Aimmune is a clinical-stage biopharmaceutical company developing proprietary product candidates and advancing a therapeutic approach for the treatment of peanut and other food allergies.
Our mission is to improve the lives of people with food allergies. We are developing desensitization treatments to help protect people with food allergies by potentially reducing the risk of allergic reactions, making accidental exposures to allergens less dangerous.
We aim to address food allergies by providing a treatment option that goes beyond the current recommendations of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our work is grounded in our founding from within the food allergy community.
We were delighted to support Allergy UK with their December masterclass in 2018 and look forward to working with them again in 2019.